* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
As a leading service provider in drug discovery and research, BOC Sciences is fully capable and committed to providing one-stop proteolysis targeting molecular drug discovery based on chimeric (Protac®). This has become a promising strategy in the field of drug discovery. With a comprehensive and advanced platform, we provide Protac® molecular discovery package services to customers around the world to meet new drug discovery goals. This includes a variety of services that cover the entire process.
Protac® (protein degradation targeted chimera) is a special protein degradation technology, which uses ubiquitin proteasome pathway, a natural protein degradation pathway in cells, to remove specific proteins that need to be degraded. A Protac® molecule consists of two key domains: the domain that specifically binds to the target protein that needs to be degraded, and the domain that binds to the E3 ubiquitination ligase, which is linked by a specific linker. Unlike traditional small molecule inhibitors, which can only regulate the activity of target proteins, Protac® can directly degrade target proteins through the protein destruction mechanism of cells themselves. Intracellular proteins with abnormal structure or function are labeled with polyubiquitin by a series of enzymes, which are then transferred to the proteasome for degradation.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Interested in our Service & Products?
Need detailed information?